235 related articles for article (PubMed ID: 20711233)
1. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
Nogueira C; Kim KH; Sung H; Paraiso KH; Dannenberg JH; Bosenberg M; Chin L; Kim M
Oncogene; 2010 Nov; 29(47):6222-32. PubMed ID: 20711233
[TBL] [Abstract][Full Text] [Related]
2. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
Kim M
Small GTPases; 2010 Nov; 1(3):161-164. PubMed ID: 21686270
[TBL] [Abstract][Full Text] [Related]
3. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
4. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M
Cancer Cell; 2011 Dec; 20(6):741-54. PubMed ID: 22172720
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
6. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
7. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
8. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.
Conde-Perez A; Gros G; Longvert C; Pedersen M; Petit V; Aktary Z; Viros A; Gesbert F; Delmas V; Rambow F; Bastian BC; Campbell AD; Colombo S; Puig I; Bellacosa A; Sansom O; Marais R; Van Kempen LC; Larue L
Nat Commun; 2015 Aug; 6():8093. PubMed ID: 26307673
[TBL] [Abstract][Full Text] [Related]
9. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
11. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
Xie X; Koh JY; Price S; White E; Mehnert JM
Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
[TBL] [Abstract][Full Text] [Related]
12. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG
Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389
[TBL] [Abstract][Full Text] [Related]
13. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
14. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
15. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
16. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
17. Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia.
Yasuta Y; Kaminaka R; Nagai S; Mouri S; Ishida K; Tanaka A; Zhou Y; Sakurai H; Yokoyama S
Sci Rep; 2024 Jan; 14(1):1525. PubMed ID: 38233537
[TBL] [Abstract][Full Text] [Related]
18. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
[TBL] [Abstract][Full Text] [Related]
19. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
[TBL] [Abstract][Full Text] [Related]
20. AKT1 Activation Promotes Development of Melanoma Metastases.
Cho JH; Robinson JP; Arave RA; Burnett WJ; Kircher DA; Chen G; Davies MA; Grossmann AH; VanBrocklin MW; McMahon M; Holmen SL
Cell Rep; 2015 Nov; 13(5):898-905. PubMed ID: 26565903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
